Article
Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
Antimicrobial agents and chemotherapy - 1 Mar 2005
Kutlin Andrei, Kohlhoff Stephan, Roblin Patricia, Hammerschlag Margaret R, Riska Paul
Abstract excerpt
Although rifamycins have excellent activity against Chlamydophila pneumoniae and Chlamydia trachomatis in vitro, concerns about the possible development of resistance during therapy have discouraged their use for treatment of chlamydial infections. Rifalazil, a new semisynthetic rifamycin with a long half-life, is the most active antimicrobial against C. pneumoniae and C. trachomatis in vitro, indicating its...
Topics
- Base Sequence
- Chlamydia trachomatis
- Chlamydophila pneumoniae
- DNA-Directed RNA Polymerases
- Drug Resistance, Bacterial
- Microbial Sensitivity Tests
- Molecular Sequence Data
- Mutation
- Rifampin
- Rifamycins